ClaudiaEstherPaba-PradaMD

Oncology • Pembroke Pines, FL

Hematologic Oncology

Physician

Join to view full profile

Dr. Paba-Prada is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Paba-Prada's full profile

Already have an account?

Office
603 N Flamingo Rd
Ste 151
Pembroke Pines, FL 33028
Phone+1 954-265-4325

Fax+1 954-436-4606

Education & Training

University of TennesseeFellowship, Hematology and Medical Oncology, 2007 - 2010
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2004 - 2007
Industrial University of Santander Faculty of MedicineClass of 2000

Certifications & Licensure

FL State Medical License 2009 - 2026
MA State Medical License 2010 - 2022
TN State Medical License 2009 - 2010
PA State Medical License 2004 - 2007
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Withdrawn
Phase 1

Publications & Presentations

PubMed

Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable ...
Paul Richardson, Myo Htut, Emma Scott, Claudia Paba Prada, Ira Gupta
Haematologica. 2024-10-03
3 citations
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.
Matthew Ho, Maria Moscvin, Soon Khai Low, Benjamin Evans, Sara Close
Leukemia & Lymphoma. 2022-10-01
61 citations
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Paul G. Richardson, Sara Bringhen, Peter M. Voorhees, Torben Plesner, Ulf-Henrik Mellqvist
The Lancet. Haematology. 2020-03-23

Abstracts/Posters

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Claudia E. Paba-Prada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Claudia E. Paba-Prada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019